Established that FAM135A is a downstream effector of GRPR signaling in prostate cancer, placing it within a defined upstream pathway rather than as an isolated factor.
Evidence RNA-seq, ChIP-seq, and GRPR pharmacological inhibition with FAM135A silencing in prostate cancer cells
- Direct mechanism by which GRPR signaling and MED15 control FAM135A transcription not resolved
- Whether FAM135A activation occurs in non-prostate contexts unknown